Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared with Statin Treatment.
Eeva Sliz,Johannes Kettunen,Michael V. Holmes,Clare Oliver Williams,Charles Boachie,Qin Wang,Minna Maennikkoe,Sylvain Sebert,Robin Walters,Kuang Lin,Iona Y. Millwood,Robert Clarke,Liming Li,Naomi Rankin,Paul Welsh,Christian Delles,J. Wouter Jukema,Stella Trompet,Ian Ford,Markus Perola,Veikko Salomaa,Marjo-Riitta Jaervelin,Zhengming Chen,Debbie A. Lawlor,Mika Ala-Korpela,John Danesh,George Davey Smith,Naveed Sattar,Adam Butterworth,Peter Wuertz
DOI: https://doi.org/10.1161/circulationaha.118.034942
IF: 37.8
2018-01-01
Circulation
Abstract:Background Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL-C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling of a large randomized statin trial, and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial. Methods 228 circulating metabolic measures were quantified by nuclear magnetic resonance spectroscopy, including lipoprotein subclass concentrations and their lipid composition, fatty acids, and amino acids, for 5,359 individuals (2,659 on treatment) in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial at 6-months post-randomization. The corresponding metabolic measures were analyzed in eight population cohorts (N=72,185) using PCSK9 rs11591147 as an unconfounded proxy to mimic the therapeutic effects of PCSK9 inhibitors. Results Scaled to an equivalent lowering of LDL-C, the effects of genetic inhibition of PCSK9 on 228 metabolic markers were generally consistent with those of statin therapy ( R 2=0.88). Alterations in lipoprotein lipid composition and fatty acid balance were similar. However, discrepancies were observed for very-low-density lipoprotein (VLDL) lipid measures. For instance, genetic inhibition of PCSK9 showed weaker effects on lowering of VLDL-cholesterol compared with statin therapy (54% vs. 77% reduction, relative to the lowering effect on LDL-C; P =2 × 10−7 for heterogeneity). Genetic inhibition of PCSK9 showed no robust effects on amino acids, ketones, and a marker of inflammation (GlycA); in contrast, statin treatment lowered GlycA levels. Conclusions Genetic inhibition of PCSK9 results in similar metabolic effects as statin therapy across a detailed lipid and metabolite profile. However, for the same lowering of LDL-C, PCSK9 inhibitors are predicted to be less efficacious than statins at lowering VLDL lipids, which could potentially translate into subtle differences in cardiovascular risk reduction.